

Prediction of the Prognosis of Somatoform Disorders Using the Minnesota Multiphasic Personality Inventory (MMPI)

Akiko Sato (✉ akikosato16@gmail.com)

Fukushima Kenritsu Ika Daigaku <https://orcid.org/0000-0002-1279-4026>

Syuntaro Itagaki

Fukushima Kenritsu Ika Daigaku

Takatomo Matsumoto

Fukushima Kenritsu Ika Daigaku

Yoko Ise

Fukushima Kenritsu Ika Daigaku

Syunya Yokokura

Fukushima Kenritsu Ika Daigaku

Tomohiro Wada

Fukushima Kenritsu Ika Daigaku

Kaoru Hayashi

Fukushima Kenritsu Ika Daigaku

Takeyasu Kakamu

Fukushima Kenritsu Ika Daigaku

Tetsuhito Fukushima

Fukushima Kenritsu Ika Daigaku

Takuya Nikaido

Fukushima Kenritsu Ika Daigaku

Shinichi Konno

Fukushima Kenritsu Ika Daigaku

Hirooki Yabe

Fukushima Kenritsu Ika Daigaku

Research

Keywords: Hy score, Consultation-liaison psychiatry, Minnesota Multifaceted Personality Inventory (MMPI), Prognostic factor, Somatoform disorders, Treatment-resistant

Posted Date: January 21st, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-150296/v1>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

1 **Prediction of the prognosis of somatoform disorders using the Minnesota**

2 **Multiphasic Personality Inventory (MMPI)**

3

4 Akiko Sato, MD, PhD¹⁾, Shuntaro Itagaki, MD, PhD¹⁾, Takatomo Matsumoto¹⁾, Yoko Ise,

5 MD, PhD¹⁾, Shunya Yokokura, MD¹⁾, Tomohiro Wada, MD¹⁾, Kaoru Hayashi¹⁾,

6 Takeyasu Kakamu, MD, PhD²⁾, Tetsuhito Fukushima, MD, PhD²⁾, Takuya Nikaido, MD,

7 PhD³⁾, Shinichi Konno, MD, PhD³⁾, Hirooki Yabe, MD, PhD¹⁾

8

9 ¹⁾ Department of Neuro Psychiatry, Fukushima Medical University, Hikarigaoka-1,

10 Fukushima 960-1295, Japan

11 ²⁾ Department of Hygiene and Preventive Medicine, Fukushima Medical University,

12 Hikarigaoka-1, Fukushima 960-1295, Japan

13 ³⁾ Department of Orthopedic Surgery, Fukushima Medical University, Hikarigaoka-1,

14 Fukushima 960-1295, Japan

15

16 The study was conducted at the Department of Neuro Psychiatry, Fukushima Medical

17 University, Japan

18 Corresponding author: Akiko Sato, MD

- 1 Department of Neuropsychiatry, School of Medicine Fukushima Medical University,
- 2 Hikarigaoka-1, Fukushima 960-1295, Japan
- 3 TEL: +81-24-547-1331, FAX: +81-24-548-6735
- 4 E-mail: akikosato16@gmail.com
- 5 All author e-mail addresses
- 6 Shuntaro Itagaki, MD, PhD; itasyun@sj8.so-net.ne.jp
- 7 Takatomo Matsumoto; takarnie@icloud.com
- 8 Yoko Ise, MD, PhD; yokoyoko.i.2.1@gmail.com
- 9 Shunya Yokokura, MD; yukkuri916shinayo@gmail.com
- 10 Tomohiro Wada, MD; aokogare@gmail.com
- 11 Kaoru Hayashi; karl-lichter@hotmail.co.jp
- 12 Takeyasu Kakamu, MD, PhD; bamboo-tk@umin.ac.jp
- 13 Tetsuhito Fukushima, MD, PhD; t-fuku@fmu.ac.jp
- 14 Takuya Nikaido, MD, PhD; tnikaido@fmu.ac.jp
- 15 Shinichi Konno, MD, PhD; skonno@fmu.ac.jp
- 16 Hirooki Yabe, MD, PhD; hyabe@fmu.ac.jp
- 17
- 18 Department of Neuropsychiatry, School of Medicine Fukushima Medical University,

1 Hikarigaoka-1, Fukushima 960-1295, Japan

2 TEL: +81-24-547-1331, FAX: +81-24-548-6735

3 E-mail: akikosato16@gmail.com

4

1 ABSTRACT

2 *Background:* To elucidate the possibility of using the Minnesota Multifaceted
3 Personality Inventory (MMPI) to predict the prognosis of somatoform disorders, which
4 are often treatment-resistant, we investigated the prognosis of somatoform disorders
5 predicted using the MMPI.

6 *Methods:* During the period from January 1, 2013, to December 31, 2017, 125 cases of
7 somatoform disorder were diagnosed in the psychiatric department of Fukushima
8 Medical University Hospital, among which, 67 were consultation-liaison psychiatry
9 cases and 58 cases were only psychiatric cases. Clinical information, MMPI scores, and
10 prognosis information were collected from medical records in each case, and then
11 statistical analysis was performed.

12 *Results:* The results showed that the unchanged group had significantly higher scores
13 than the improved group on only the Hy scale. Receiver operating characteristic
14 analysis of the Hy scale scores of the improved and unchanged group was then
15 conducted to calculate a cutoff value. The cutoff point was 73.5 with a sensitivity of
16 0.557 and a specificity of 0.717.

17 *Conclusion:* For patients diagnosed with somatoform disorder who had an MMPI Hy
18 scale score higher than the cutoff value, improvement with conventional supportive

1 psychotherapy or drug therapy was predicted to be difficult. Therefore, the cutoff point
2 identified in this study appears to be an important index for selecting treatment for
3 somatoform disorders.

4

5 *Keywords:*

6 Hy score

7 consultation-liaison psychiatry

8 Minnesota Multifaceted Personality Inventory (MMPI)

9 Prognostic predictor

10 Somatoform disorders

11 Treatment-resistant

12

1 **Background**

2 Somatoform disorders are included in the traditional clinical classification of
3 neuroses and are also classified as neurotic disorders according to the 10th revision of
4 the International Classification of Diseases (ICD-10) [1] and the Diagnostic and
5 Statistical Manual of Mental Disorders, fourth edition, text revision (DSM-IV-TR) [2,3].
6 Chronic pain is classified into nociceptive pain, neuropathic pain, and psychogenic pain
7 [4]. Among these types, psychogenic pain is classified as persistent somatoform pain
8 disorder among the somatoform disorders in the ICD-10, and as chronic pain disorder in
9 the DSM-IV-TR [5]. In addition to the distress of experiencing the symptoms
10 themselves, chronic pain is likely to cause secondary disorders such as psychiatric
11 problems and a decreased ability to carry out activities of daily living. Therefore,
12 chronic pain is a serious disorder that cannot be overlooked, especially economically, as
13 it can lead to labor loss in the productive population and increased medical expenses
14 because of repeated medical examinations and long-term treatment [6].

15 As pharmacotherapy, selective serotonin reuptake inhibitors (SSRIs), antipsychotic
16 drugs, and benzodiazepine anxiolytics have been considered to be useful to some extent
17 for somatoform disorders[7]. However, although research elucidating the neural basis of
18 somatoform disorders is currently in progress, no effective treatment has been

1 established. Therefore, recovery from somatoform disorders is often difficult and
2 largely dependent on psychosocial treatment [8].

3 Since 1996, consultation-liaison psychiatry services, which consist of medical teams
4 including orthopedists, psychiatrists, and other co-medical staffs such as nurses,
5 physical therapists, clinical psychologists, clinical pharmacists, and social workers, have
6 been conducted in Fukushima Medical University Hospital(FMUH). These conferences
7 are held once a month and involve discussions on how to deal with the psychosomatic
8 problems of patients diagnosed with somatoform disorder. Owing to these conferences,
9 we have accumulated substantial MMPI data for these cases. It has been considered that
10 many patients who have psychosocial personality problems or psychiatric disorders
11 have previously consulted an orthopedist because of chronic pain and numbness or have
12 not been satisfied with conventional orthopedic treatment [5,9]. The multidisciplinary
13 nature of this conference is based on recognition that “team medical care,” in which
14 related medical staffs cooperate and provide patient-centered medical care, is essential
15 to promote effective treatment and solve various problems. This liaison psychiatry
16 approach is characterized by a basic policy of the orthopedist remaining involved in
17 treatment because even if the patient has psychiatric, psychological, or social problems,
18 the chief complaint is a physical symptom [5,9].

1 Numerous studies have reported personality tendencies in patients with somatoform
2 disorders based on the MMPI [10–18]. However, to our knowledge, no studies have
3 assessed the utility of the MMPI as an prognostic predictor of somatoform disorders,
4 and only a few reports have used it to predict outcomes of surgical treatment for chronic
5 back pain [19–22]. In FMUH, the MMPI has been continuously conducted, and data
6 have been accumulated on the cases discussed in the liaison conferences for the purpose
7 of evaluating whether patients with chronic pain suffer from latent paranoia, depression,
8 or other psychiatric disorders, as well as whether their personality may affect their
9 symptoms [23,24].

10 Although the MMPI has mainly been used for diagnosis and assessment, if it could
11 be used for the prediction of prognosis of somatoform disorders, treatment would be
12 expected to proceed more smoothly because more effective interventions could be
13 started at an early stage, and the patient could recognize the therapeutic effects sooner.
14 In addition, considering that MMPI takes quite much time to be completed due to a
15 large number of question items, over 500, if key items predicting negative outcome
16 could be identified, it should be more useful and reduce psychological burden of target
17 patients.

18 The present study has two purposes; one is to clarify psychological and biological

1 factors associating with negative outcome of somatoform disorders, another is to
2 identify key items of MMPI predicting negative outcome. Therefore, we collected the
3 data from patients who all had received MMPI in clinical settings, classified them into
4 two groups (improvedgroup vs. unchanged group) based on the chart review, and
5 examined two groups.

6 **Methods**

7 *Participants* During the period from January 1, 2013, to December 31, 2017, 125
8 cases of somatoform disorder were diagnosed at the psychiatric department of
9 Fukushima Medical University Hospital based on the ICD-10 [1]. Among these cases,
10 67 were associated with the consultation-liaison psychiatry approach, and 58 with only
11 the psychiatric approach. Also among these cases, 80 were classified as Persistent
12 somatoform pain disorder, 31 were as Somatization disorder, 8 were as Undifferentiated
13 somatoform disorder, 4 were as Somatoform autonomic dysfunction, and 2 were as
14 Other somatoform disorders. All these cases were treated conventional supportive
15 psychotherapy or pharmacotherapy.

16

17 *Measurements and procedures*

18 The Minnesota Multifaceted Personality Inventory (MMPI) is a standardized

1 psychometric test of adult personality and psychopathology based on the questionnaire
2 method developed by Hathaway and McKinley of the University of Minnesota in the
3 late 1930s [25,26]. The MMPI is composed of 550 items, and hundreds of additional
4 scales have been developed. In the United States, a re-standardization of the MMPI
5 began around the end of the 1980s because of problems with the wording of the item
6 text and inadequate standardization procedures in the original version. The second
7 version, the MMPI-2, maintained continuity with the original. The Japanese version of
8 the MMPI was published in 1963, but mistranslations and problems with
9 standardization procedures were apparent from the beginning, and efforts to resolve
10 these problems began around 1990. The New Japan Version of the MMPI was published
11 in 1993, and is still currently used in Japan [25,26]. The original purpose of the MMPI
12 was to provide objective information necessary for psychiatric diagnosis. Subsequently,
13 the purpose shifted to personality assessment, and thus, it is now one of the most
14 frequently used personality tests around the world [25,26]. Actually, more than 12,000
15 papers have been published on the MMPI and MMPI-2 since the late 1940s [27].

16 From medical records from May 1, 2019 to July 31, 2019, we collected
17 information on factors that may affect the prognosis of somatoform disorders for each
18 case, including age, gender, duration of illness, the comorbidity of developmental

1 disorders, decreased cerebral blood flow, history of surgery, MMPI profile, and presence
2 of the conversion V pattern on the MMPI. Then, we identified patients indicating
3 negative outcome based on the following information obtained from the charts : (1)
4 Subjective estimation regarding pain, (2) Social function including ADL. This group
5 was named “improved group (IG)” and others named “non-improved group (NIG)”.

6 We profiled four validity scales (P, L, F, K; Table 1) and 10 clinical scales (Hs, D,
7 Hy, Pd, Mf, Pa, Pt, Sc, Ma, Si; Table 2) as basic scales for the MMPI [9,28]. The
8 interpretation of the conversion V pattern is shown in Table 3. Decreased cerebral blood
9 flow was defined as when a radiologist reported that “there was low blood flow(Vd less
10 than 30ml/ml by ARG method)” based on N-isopropyl-(¹²³I)p-iodoamphetamine
11 computed tomography, regardless of the brain region. The comorbidity of
12 developmental disorders was defined as when a psychiatrist noted autism spectrum
13 disorder (ASD), attention deficit hyperactivity disorder (ADHD), or pervasive
14 developmental disorder in a patient’s medical records. A history of surgery was defined
15 as any descriptions of orthopedic surgery in a patient’s medical records.

16

17 *Statistical analysis*

18 We descriptively compared each factor between the IG and NIG groups. Differences

1 between groups were analyzed using the Mann–Whitney U test, the Student *t*-test, and
2 the chi-squared test. Among the MMPI scales, receiver operating characteristic (ROC)
3 curves that showed a significant difference between the IG and NIG were created for the
4 Hy scale. The area under the curve (AUC) and 95% confidence intervals (CIs) were
5 calculated, as was the cutoff value using Youden’s index. Statistical analysis was
6 performed using SPSS ver. 26 (SPSS, Chicago, IL, USA), and *p* values < 0.05 were
7 considered statistically significant.

8

9 **Results**

10 In total, 125 patients (49 males, 76 females; mean age \pm standard deviation [SD],
11 51.9 \pm 17.4 years) participated in this study.

12

13 *Prognostic comparison of the participants’ basic characteristics (Table 4)*

14 No significant differences in age, gender, duration of illness, the comorbidity of
15 developmental disorders, decreased cerebral blood flow, or history of surgery were
16 observed between the IG and NIG. The mean age \pm SD of the IG and NIG were 49.3 \pm
17 17.8 and 53.8 \pm 17.5, respectively (*p* = 0.167). Regarding the gender ratio, 16 (34.6%)
18 males and 30 females (65.2%) were in the improved group, and 33 males (41.8%) and

1 46 (58.2%) females were in the unchanged group ($p = 0.44$). The median duration of
2 illness in the IG was 35 months (25th–75th percentile = 24–91), and that in the NIG was
3 54 months (25th–75th percentile = 24–120; $p = 0.168$). The numbers of patients with
4 decreased cerebral blood flow were 14 (51.9%) in the IG and 30 (57.7%) in the NIG (p
5 = 0.62). The numbers of patients who had a history of surgery were 15 (32.6%) in the
6 IG and 26 (32.9%) in the NIG ($p = 0.972$).

7 No significant differences were found in the presence of the conversion V pattern
8 between the IG and NIG (17.4% vs. 17.7%, respectively; $p = 0.963$). Regarding the
9 presence of developmental disorders, the comorbidity rate of developmental disorders
10 was 10.9% in the IG and 25.3% in the NIG; this rate tended to be higher in the
11 unchanged than in the improved group, but this difference was not significant ($p =$
12 0.051).

13

14 *Prognostic comparison of each MMPI scale (Table 5)*

15 Regarding the results of the Student t -test for each scale of the MMPI, the NIG
16 group showed a significantly higher value than the IG on the Hy scale (IG, 66.2 ± 15.4
17 vs. NIG, 73.5 ± 12.4 ; $p = 0.04$). The scores on the ? scale were 45.4 ± 11.1 for the IG
18 and 49.0 ± 9.3 for the NIG; although the IG tended to have lower scores, this difference

1 was not significant ($p = 0.051$).

2

3 *ROC curves of the Hy score for all participants (Figure 1)*

4 The results of the ROC analysis performed using the Hy scores of all participants
5 indicated a significant difference between the IG and NIG groups, with an AUC (95%
6 CI) of 0.652 (0.55–0.753). The cutoff point was 73.5 with a sensitivity of 0.557 and a
7 specificity of 0.717.

8

9 **Discussion**

10 The MMPI can identify the personality of subjects from multiple aspects based on
11 answers to questions assessing, for example, hypochondriac, obsessive, and compulsive
12 tendencies. A configuration in which the Hypochondriasis (Hs) and Hysteria (Hy) scale
13 are $T = 70$ or more and the T score of these two scales is 10 or higher than that of the
14 Depression (D) scale is called the “conversion V” pattern. The conversion V pattern
15 suggests that subjects tend to “replace” their psychological problems with socially
16 acceptable ones, such as physical complaints. Tendencies to escape from a situation
17 through physical complaints, to try and control others, and to suppress or deny the
18 problem are then presumed [9,10].

1 Then, We carefully discuss each result in detail as follows.

2

3 *Comparison between the improved and unimproved prognosis groups*

4 We selected basic characteristics such as age, gender, duration of illness, the
5 comorbidity of developmental disorders, decreased cerebral blood flow, history of
6 surgery, and the conversion V pattern on the MMPI as factors that may affect the
7 outcome of somatoform disorders. An analysis of each outcome group did not reveal any
8 significant differences. Regarding the cerebral blood flow, it has been reported to be
9 decreased in patients with chronic pain [29]. But no significant differences were found in
10 this study. But the NIG was more likely to have developmental disorders. It has been
11 reported that among developmental disorders in children, both ASD and ADHD are
12 associated with a high rate of chronic pain [30,31]. For ASD and ADHD, it is said that a
13 therapeutic effect can be obtained by combining psychosocial treatment in addition to
14 pharmacotherapy [32,33]. Therefore, when the comorbidity of developmental disorders
15 is recognized, it is thought that somatoform disorders could be improved by performing
16 a therapeutic intervention particularly for developmental disorders. In addition,
17 analysis of each scale of the MMPI showed that only the Hy scale had a significant
18 difference, indicating that the NIG had higher scores on the Hy scale than the improved

1 group. We discuss about what this result mean in detail as follows.

2 *Significance of high scores on the Hy scale*

3 A high score on the Hy scale indicates a tendency to avoid responsibilities related to
4 psychological conflicts by converting these to physical symptoms (a tendency to use
5 conversion symptoms). It also means that individuals with a high Hy score tend to be
6 immature and lack self-insight, indicating that their relationships with other people are
7 often superficial, even though they may appear to be appear to be socially well adopted
8 [9]. A significant difference was observed between the IGand NIG only in this Hy scale
9 score. Therefore, ROC analysis was performed on the Hy score for the IG and NIG,
10 resulting in a cutoff score of 73.5. Previous studies have reported that patients with
11 chronic pain show higher Hy scores [34,35]. On the other hand, when scores on the K
12 and Hs scales are low, only a high Hy scale score is considered insufficient to consider
13 whether the pain is psychogenic [36,37].

14 However, even if only a high Hy scale score is insufficient to determine whether
15 the pain is psychogenic, a high Hy score is still considered to indicate a remarkably
16 severe degree of distress in terms of physical symptoms. In addition, all cases analyzed
17 in this study had already been diagnosed as somatoform disorder. Few reports have been
18 published on the outcome viewpoint of the MMPI for somatoform disorders, and no

1 reported cases have shown meaningful profiles or characteristics for each scale [38].

2 The cutoff point calculated in this study was 73.5, which was even higher than the
3 score generally considered to be abnormal (70). If the Hy scale score of a patient
4 diagnosed with a somatoform disorder is higher than this cutoff value, he or she is
5 considered difficult to treat with conventional supportive psychotherapy or
6 pharmacotherapy. In such cases, it may be necessary to consider psychiatric
7 “multidisciplinary” treatment, which is a further enhancement of conventional
8 treatments [39–43], e.g., psychosocial treatment such as cognitive behavioral therapy
9 [44–48] or mindfulness therapy [49], pharmacotherapy, and environmental adjustments.
10 Therefore, this cutoff point appears to be an important index for treatment selection in
11 patients with somatoform disorder. However, since this was a retrospective study, if the
12 Hy scale score exceeds the cutoff point, prospective studies are needed to compare the
13 prognoses of the following two groups: one that is provided with therapeutic
14 interventions such as augmented pharmacotherapy and psychotherapy, psychosocial
15 treatment, and environmental adjustments, and another that receives standard therapy
16 (general pharmacotherapy and supportive psychotherapy).

17

18 *Limitations*

1 The classification of the outcome of somatoform disorder among the current group
2 used in this study was based on only the chart review not more reliable ways such as
3 diagnostic (structured) interviews or self-administered questionnaires.

4

5 *Conclusions*

6 In this study, we performed a basic examination regarding the possibility of
7 predicting the prognosis of patients with somatoform disorders based on the MMPI. The
8 results suggested that the Hy scale score might influence the prognosis. The cases
9 exceeding the cutoff point based on ROC analysis are considered difficult to treat with
10 conventional supportive psychotherapy or pharmacotherapy. Therefore, this cutoff point
11 could be an important index in considering treatment options for improving the
12 prognosis of patients with somatoform disorders.

13

14 **Declarations**

15 **Ethics approval and consent to participate** : This study was approved by the Ethics
16 Committee of Fukushima Medical University (approval No. 2941).

17

18 **Consent for publication** : Consent to publish this study was provided, and all

1 participants signed an informed consent form.

2

3 **Availability of data and material** : Detailed data are available from the corresponding
4 authors upon reasonable request.

5

6 **Competing interests** : The authors have no competing interests to report.

7

8 **Funding** : This research did not receive any specific grant from funding agencies in the
9 public, commercial, or not-for-profit sectors.

10

11 **Authors' contributions** : AS conceived the study. AS and KH collected the data. AS
12 and TK analyzed the data. All authors contributed to data analysis, drafting and
13 critically revising the paper, gave final approval of the version to be published, and
14 agreed to be accountable for all aspects of the work.

15

16 **Acknowledgements** : We sincerely thank all of the orthopedic surgeons, psychiatrists,
17 and medical staffs involved in liaison therapy at Fukushima Medical University.

18

1 **Authors' information** : Department of Neuro Psychiatry, Fukushima Medical

2 University, Hikarigaoka-1, Fukushima 960-1295, Japan

3

4

1 **References**

2 [1] World Health Organization: ICD-10, the ICD-10 Classification of Mental and
3 Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines, World Health
4 Organization; 1992.

5 [2] American Psychiatric Association; Diagnostic and Statistical Manual of Mental
6 Disorders: DSM IV, American Psychiatric Association; 1994.

7 [3] T. Okuma; Modern Clinical Psychiatry, 12th ed.: Kaneharashuppan; 2013.

8 [4] K. Watanabe, S. Konno. Musculoskeletal pain management. Prog Med;2013;33 :9–
9 12.

10 [5] H. Mashiko Indefinite complaints in orthopedic surgery. Japanese Journal of Clinical
11 Psychiatry;2012; 41: 275–281.

12 [6] Y. Mizuno, M. Fukunaga, Y. Nakai. Differences in psychological characteristics
13 between chronic pain patients and other psychosomatic (mind–body) disease patient.
14 The Journal of the Japanese Society for the Study of Chronic Pain;2004; 23: 193–199.

15 [7] Y. Nagoshi. Recent advances in pharmacotherapy for somatic symptom and related
16 disorders (somatoform disorders). Japanese Journal of Psychosomatic Medicine.2019;
17 59; 554–559.

18 [8] M. Sellbom, D. Wygant, M. Bagby. Utility of the MMPI-2-RF in detecting non-

- 1 credible somatic complaints, *Psychiatry Res.*2012; 197;295–301.
- 2 [9] K. Otani. Liaison treatment for patients with chronic pain of locomotive organ-
3 experience of Fukushima Medical University Hospital, *Japanese Journal of*
4 *Psychosomatic Medicine.*2011; 51;709–714.
- 5 [10] B. Naylor, S. Boag, S.M. Gustin. New evidence for a pain personality? A critical
6 review of the last 120 years of pain and personality, *Scand. J. Pain.*2017; 17; 58–67.
- 7 [11] A.A. Vendrig. The Minnesota Multiphasic Personality Inventory and chronic pain,
8 a conceptual analysis of a long-standing but complicated relationship. *Clin. Psychol.*
9 2000;Rev. 20; 533–559.
- 10 [12] D.A. Fishbain, B. Cole, R.B. Cutler, J. Lewis, H.L. Rosomoff, R.S.
11 Rosomoff.Chronic pain and the measurement of personality: do states influence
12 traits?.,*Pain Med.*2006; 7;509–529.
- 13 [13] J. Dersh, P.B. Polatin, R.J. Gatchel.Chronic pain and psychopathology, research
14 findings and theoretical considerations, *Psychosom. 2002;Med.* 64;773–786.
- 15 [14] G. Garyfallos, A. Adamopoulou, A. Karastergiou, M. Voikli, N. Ikonomidis, S.
16 Donias, et al.. Somatoform disorders: comorbidity with other DSM-III-R psychiatric
17 diagnoses in Greece, *Compr. Psychiatry.*1999; 40;299–307.
- 18 [15] M. Balasanyan, K.B. Boone, A. Ermshar, D. Miora, M. Cottingham, T.L. Victor, et

- 1 al..Examination of the Modified Somatic Perception Questionnaire (MSPQ) in a large
2 sample of credible and noncredible patients referred for neuropsychological testing,
3 Clin. Neuropsychol. 2018;32; 165–182
- 4 [16] J.A. Koelen, E.H.M. Eurelings-Bontekoe, S.A.M. van Broeckhuysen-Kloth, W.M.
5 Snellen, P. Luyten. Social cognition and levels of personality organization in patients
6 with somatoform disorders, a case-control study.2014; J. Nerv. Ment. Dis. 202;217–223
- 7 [17] A.A. Vendrig, J.J. Derksen, H.R. de Mey. MMPI-2 Personality Psychopathology
8 Five (PSY-5) and prediction of treatment outcome for patients with chronic back pain.
9 2000;J. Pers. Assess;74;423–438.
- 10 [18] M. Hasegawa, S. Hattori, M. Ohnaka, K. Ishizaki, F. Goto.Psychological
11 characteristics of chronic pain patients. 1998;Journal of Japan Society of Pain Clinicians
12 5;30–35.
- 13 [19] D. Barnes, R.J. Gatchel, T.G. Mayer, J. Barnett. Changes in MMPI profile levels of
14 chronic low back pain patients following successful treatment.1990; J. Spinal Disord. 3;
15 353–355.
- 16 [20] C. McCreary, B. Naliboff, M. Cohen.A comparison of clinically and empirically
17 derived MMPI groupings in low back pain patients.1989; J. Clin. Psychol. 45;560–570.
- 18 [21] D.E. Williams, J.K. Thompson, J.D. Haber, J.M. Raczynski. MMPI and headache:

1 a special focus on differential diagnosis, prediction of treatment outcome, and patient-
2 treatment matching.1986; Pain 24; 143–158.

3 [22] C. McCreary, J. Turner, E. Dawson.The MMPI as a predictor of response to
4 conservative treatment for low back pain.1979;J. Clin. Psychol. 35;278–284.

5 [23] S. Kasahara. Psychiatric approach for the patients with chronic pain, Japanese
6 Journal of Clinical Psychiatry.2013;42;739–748.

7 [24] T. Nikaido, S. Yabuki, K. Otani, K. Watanabe, K. Kato, Y. Kobayashi, et
8 al..Scientific approach for pain based on biopsychosocial model: liaison approach for
9 chronic low back pain.2016; Journal of Musculoskeletal Pain Research 8; 192–198.[25]
10 T. Shioya.History of MMPI, The Society for MMPI New Japanese Version MMPI.2004.
11 <http://www.mmpi-new.com/history>.Accessed 18 April 2020. [26] H. Noro, W. Arakawa,
12 S. Ide. MMPI Handbook, Basics to Understand, Japanese Clinical Society for the Study
13 of MMPI.Tokyo: Kongoshuppan; 2014.

14 [27] J.N. Butcher. MMPI-2 in Psychological Treatment. Oxford: Oxford University
15 Press; 1990.

16 [28] Kanazawa University Psychology Laboratory.MMPI Japanese Language
17 Implementation Guide (Kanazawa University version). Kanazawa: Kanazawa
18 University Psychology Laboratory;1965.

- 1 [29] Shin-ichi Konno, Miho Sekiguchi. Association between brain and low back
2 pain.2018;J Orthop Sci 23; 3-7.
- 3 [30] C.W. Lipsker, S. Bölte, T. Hirvikoski, M. Lekander, L. Holmström, R.K. Wicksell.
4 Prevalence of autism traits and attention-deficit hyperactivity disorder symptoms in a
5 clinical sample of children and adolescents with chronic pain.2018; J. Pain Res. 8;
6 2827–2836.
- 7 [31] C. Baeza-Velasco, D. Cohen, C. Hamonet, E. Vlamynck, L. Diaz, C. Cravero, et
8 al..Autism, joint hypermobility-related disorders and pain.2018; Front. Psychiatry 9 ;
9 656.
- 10 [32] J.J.S. Kooij, D. Bijlenga, L. Salerno, R. Jaeschke, I. Bitter, J. Balázs, et al..
11 Updated European Consensus Statement on diagnosis and treatment of adult
12 ADHD.2019; Eur. Psychiatry 56;14–34.
- 13 [33] L. Bishop-Fitzpatrick, N.J. Minshew, S.M. Eack.A systematic review of
14 psychosocial interventions for adults with autism spectrum disorders. 2013;J. Autism
15 Dev. Disord. 43;687–694.
- 16 [34] S.R. Ornduff, A.F. Brennan, C.L. Barrett.The Minnesota Multiphasic Personality
17 Inventory (MMPI) Hysteria (Hy) scale, scoring bodily concern and psychological denial
18 subscales in chronic back pain patients.1988; J. Behav. Med. 11;131–146.

- 1 [35] B.N. Kinder, G. Curtiss, S. Kalichman. Anxiety and anger as predictors of MMPI
2 elevations in chronic pain patients.1986; J. Pers. Assess. 50;651–661.
- 3 [36] M. Aragona, L. Tarsitani, S. De Nitto, M. Inghilleri. DSM-IV-TR “pain disorder
4 associated with psychological factors” as a nonhysterical form of somatization.2008;
5 Pain Res. Manag.;13;13–18.
- 6 [37] R.E. McGrath, W.B. O’Malley. The assessment of denial and physical complaints:
7 the validity of the Hy scale and associated MMPI signs.1986; J. Clin.
8 Psychol. ;42 ;754–760.
- 9 [38] A.M. Tarescavage, J. Scheman, Y.S. Ben-Porath. Prospective comparison of the
10 Minnesota Multiphasic Personality Inventory-2 (MMPI-2) and MMPI-2-Restructured
11 Form (MMPI-2-RF) in predicting treatment outcomes among patients with chronic low
12 back pain.2018; J. Clin. Psychol. Med. Settings 25;66–79.
- 13 [39] J.A. Koelen, J.H. Houtveen, A. Abbass, P. Luyten, E.H. Eurelings-Bontekoe, S.A.
14 Van Broeckhuysen-Kloth, et al.. Effectiveness of psychotherapy for severe somatoform
15 disorder: meta-analysis.2014; Br. J. Psychiatry 204;12–19.
- 16 [40] A.M. Sutherland, J. Nicholls, J. Bao, H. Clarke. Overlaps in pharmacology for the
17 treatment of chronic pain and mental health disorders.2018; Prog.
18 Neuropsychopharmacol. Biol. Psychiatry;87; 290–297.

- 1 [41] N. van Dessel, M. den Boeft, J.C. van der Wouden, M. Kleinstäuber, S.S. Leone,
2 B. Terluin, et al..Non-pharmacological interventions for somatoform disorders and
3 medically unexplained physical symptoms (MUPS) in adults.2014; Cochrane Database
4 Syst. Rev. ;CD011142,.<https://doi.org/10.1002/14651858.CD011142.pub2>. Accessed 18
5 April 2020.
- 6 [42] H. van Ravesteijn. [Mindfulness-based cognitive therapy for patients with
7 somatoform disorders].2016; Tijdschr. Psychiatr; 58;198–206.
- 8 [43] K. Cyranka, K. Rutkowski, M. Mielimąka, J.A. Sobański, B. Smiatek-Mazgaj, K.
9 Klasa, et al.. Changes in personality functioning as a result of group psychotherapy with
10 elements of individual psychotherapy in persons with neurotic and personality disorders
11 - MMPI-2.2016; Psychiatr. Pol.; 50;105–126.
- 12 [44] S.L. Kurlansik, M.S. Maffei. Somatic Symptom Disorder.2016; Am. Fam.
13 Physician;93; 49–54.
- 14 [45] A. Yoshino, Y. Okamoto, R. Jinnin, K. Takagaki, A. Mori, S. Yamawaki.Role of
15 coping with negative emotions in cognitive behavioral therapy for persistent
16 somatoform pain disorder: is it more important than pain
17 catastrophizing?.2019;Psychiatry Clin. Neurosci. ;73;560–565.
- 18 [46] A. Yoshino, Y. Okamoto, M. Doi, M. Horikoshi, K. Oshita, R. Nakamura, et al..

1 Effectiveness of group cognitive behavioral therapy for somatoform pain disorder
2 patients in Japan: a preliminary non-case-control study;;2015;Psychiatry Clin.
3 Neurosci. ;69;763–772.

4 [47] J. Liu, N.S. Gill, A. Teodorczuk, Z.J. Li, J. Sun.The efficacy of cognitive
5 behavioural therapy in somatoform disorders and medically unexplained physical
6 symptoms: a meta-analysis of randomized controlled trials.2019;J. Affect. Disord.;245 ;
7 98–112.

8 [48] A. Sumathipala.What is the evidence for the efficacy of treatments for somatoform
9 disorders? A critical review of previous intervention studies.2007;Psychosom.
10 Med. ;69;889–900.

11 [49] L. Hilton, S. Hempel, B.A. Ewing, E. Apaydin, L. Xenakis, S. Newberry, et al..
12 Mindfulness meditation for chronic pain: systematic review and meta-analysis.2017;
13 Ann. Behav. Med.;51;199–213.

14

15

16

17 **Figure legend**

18


19 **Fig. 1.** Receiver operating characteristic (ROC) curves of the Hysteria (Hy) scale score

1 on the Minnesota Multiphasic Personality Inventory (MMPI) for all participants. ROC
2 analysis was performed using the Hy scale scores for all participants that showed a
3 significant difference between the improved and unchanged groups; the area under the
4 curve (AUC) (95% confidence interval) was 0.652 (0.55–0.753), as calculated using
5 Youden's index, with a cutoff value of 73.5.

6

7

Figures



AUC (95% confidence interval)	<i>p</i>	Cutoff value
0.652 (0.55–0.753)	0.004	73.5

Figure 1

Receiver operating characteristic (ROC) curves of the Hysteria (Hy) scale score on the Minnesota Multiphasic Personality Inventory (MMPI) for all participants. ROC analysis was performed using the Hy scale scores for all participants that showed a significant difference between the improved and

unchanged groups; the area under the curve (AUC) (95% confidence interval) was 0.652 (0.55–0.753), as calculated using Youden's index, with a cutoff value of 73.5.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Tables.pdf](#)